A Single Center Experience of Cladribine, Cytarabine, Filgrastim and Mitoxantrone (CLAG-M regimen) in High-Risk or Relapsed/Refractory, Acute Myeloid Leukemia (AML)

Vidal Valerie; Hamri Laila; Marceau-Renaut Alice; De Fontbrune Flore Sicre; Eclache Virginie; Osman Nevine; Papoular Benjamin; Lusina Daniel; Brechignac Sabine; De Latour Regis Peffault; Preudhomme Claude; Gardin Claude; Braun Thorsten

首页> 外文期刊>Blood: The Journal of the American Society of Hematology >A Single Center Experience of Cladribine, Cytarabine, Filgrastim and Mitoxantrone (CLAG-M regimen) in High-Risk or Relapsed/Refractory, Acute Myeloid Leukemia (AML)

【24h】

A Single Center Experience of Cladribine, Cytarabine, Filgrastim and Mitoxantrone (CLAG-M regimen) in High-Risk or Relapsed/Refractory, Acute Myeloid Leukemia (AML)

机译：在高风险或复发/难治性，急性髓白血病（AML）中的克拉酮嗪，溶细胞素，丝贼集和丝洛氏菌（Clag-M方案）的单一中心体验

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology》 |2018年第novaelatreatmentappr期|共2页
作者
Vidal Valerie; Hamri Laila; Marceau-Renaut Alice; De Fontbrune Flore Sicre; Eclache Virginie; Osman Nevine; Papoular Benjamin; Lusina Daniel; Brechignac Sabine; De Latour Regis Peffault; Preudhomme Claude; Gardin Claude; Braun Thorsten;
展开▼
作者单位

Univ Paris XIII Clin Hematol Avicenne Hosp APHP Bobigny France;

Univ Paris XIII Clin Hematol Avicenne Hosp APHP Bobigny France;

Univ Hosp Lille Mol Biol Lille France;

Univ Paris VII Transplantat Unit St Louis Hosp APHP Paris France;

Univ Paris XIII Lab Hematol Avicenne Hosp APHP Bobigny France;

Univ Paris XIII Dept Pharmacol Avicenne Hosp APHP Bobigny France;

Univ Paris XIII Clin Hematol Avicenne Hosp APHP Bobigny France;

Univ Paris XIII Lab Hematol Avicenne Hosp APHP Bobigny France;

Univ Paris XIII Clin Hematol Avicenne Hosp APHP Bobigny France;

Univ Paris VII Transplantat Unit St Louis Hosp APHP Paris France;

Univ Hosp Lille Mol Biol Lille France;

Univ Paris XIII Clin Hematol Avicenne Hosp APHP Bobigny France;

Univ Paris XIII Clin Hematol Avicenne Hosp APHP Bobigny France;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类血液及淋巴系疾病;
关键词

相似文献

外文文献
中文文献
专利

1. A Single Center Experience of Cladribine, Cytarabine, Filgrastim and Mitoxantrone (CLAG-M regimen) in High-Risk or Relapsed/Refractory, Acute Myeloid Leukemia (AML) [J] . Vidal Valerie, Hamri Laila, Marceau-Renaut Alice, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：在高风险或复发/难治性，急性髓白血病（AML）中的克拉酮嗪，溶细胞素，丝贼集和丝洛氏菌（Clag-M方案）的单一中心体验
2. Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure [J] . JaglalM.V., DuongV.H., BelloC.M., Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis . 2014,第4期

机译：克拉屈滨，阿糖胞苷，非格司亭和米托蒽醌（CLAG-M）与氮杂核苷失败后骨髓增生异常综合征急性髓性白血病标准诱导相比
3. Efficacy and Safety of C-CAG Regimen (cladribine in combination with granulocyte colony-stimulating factor, low-dose cytarabine and aclarubicin) in Patients with Refractory/Relapsed Acute Myeloid Leukemia: A Phase 2, Single Center, Single Arm Study [J] . Wang Hua, Lu Yue Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：C-CAG方案（CLADRIBINE与粒细胞菌落刺激因子，低剂量红细胞和AClarubicin组合）的疗效和安全性在难治性/复发急性髓性白血病患者中：2，单中心，单臂研究
4. K-Means Clustering on 3^rd order polynomial based normalization of Acute Myeloid Leukemia (AML) and Acute Lymphocyte Leukemia (ALL) [C] . Mehdi A.M., Sehgal M.S., Zayegh A., Electrical Engineering, 2009. ICEE '09 . 2009

机译：基于3 ^{rd 多项式的K均值聚类基于急性髓细胞白血病（AML）和急性淋巴细胞白血病（ALL）的归一化}
5. Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study [D] . Harada Yasuhiko, 原田靖彦 2019

机译：根据2017年日本成人白血病研究组（JALSG）AML201研究治疗的成人急性髓性白血病患者的遗传学预测，根据2017 ELN风险分层进行预后分析
6. Comparison of High-Dose Cytarabine Mitoxantrone and Pegaspargase (HAM-pegA) to High-Dose Cytarabine Mitoxantrone Cladribine and Filgrastim (CLAG-M) as First-Line Salvage Cytotoxic Chemotherapy for Relapsed/Refractory Acute Myeloid Leukemia [O] . Ciera L. Patzke, Alison P. Duffy, Vu H. Duong, 2020

机译：高剂量阿糖胞苷米托蒽醌和天马酰胺酶（HAM-pegA）与高剂量阿糖胞苷米托蒽醌克拉屈滨和非格司亭（CLAG-M）作为一线挽救性细胞毒性化学疗法对复发/难治性急性髓细胞白血病的比较
7. Cladribine with Granulocyte Colony‐Stimulating Factor, Cytarabine, and Aclarubicin Regimen in Refractory/Relapsed Acute Myeloid Leukemia: A Phase II Multicenter Study [O] . Hua Wang, Liang Wang, Chun Li, 2020

机译：用粒细胞殖民群刺激因子，糖碱和难治性/复发急性髓鞘细胞蛋白酶的刺激因子，溶氨基胺和Aclarubicin中的菌根：II期多中心研究

A Single Center Experience of Cladribine, Cytarabine, Filgrastim and Mitoxantrone (CLAG-M regimen) in High-Risk or Relapsed/Refractory, Acute Myeloid Leukemia (AML)

著录项

相似文献

相关主题

期刊订阅